Labcorp Holdings Inc.LHNYSE

Overview Intelligence Charts News Fundamentals

DCF Valuation

⚠️Model Warnings

•Revenue projections show 12% decline from peak. Analyst estimates may reflect secular headwinds or transition period.

DCF Valuation Summary

Strong Buy

Fair Value: $383.22 per share(market-calibrated)

+35.4%

Upside to Fair Value

Current

$282.99

Pure Model

$388.18

Fair Value

$383.22

Bull Case

$439.70

Bear Case

$334.63

Market Reality Check

Model Terminal Growth

3.00%

Market-Implied Growth

2.33%

Calibrated Growth

2.83%

Fair value uses 75% model / 25% market-implied terminal growth. Pure model: $388.18.

What's Driving This Ratingfor LH

✓

CapEx already efficient

CapEx at 3.33% of revenue is already at or below sector maintenance level. No normalization needed — cash conversion is already strong.

↑

Margin expansion modeled

Current EBIT margin is 12.08% — below the sector mature average of 20.00%. Model expands margins as the business scales and operating leverage kicks in. Year 10 EBIT reaches $2.3B (17.41% margin).

⚠

Analyst growth decelerates sharply

Revenue growth drops from 5.19% in Year 1 to -12.20% by Year 5 (per analyst consensus). That's below the 3.00% terminal rate, so growth re-accelerates in Years 6-10 — a generous assumption. This growth deceleration is a key reason the model may undervalue the stock if growth re-accelerates.

↔

Perpetuity and exit methods disagree

Perpetuity growth gives $318.73/share (23.4x terminal FCF) while exit multiple gives $457.64/share (35.9x terminal FCF). The 24x EV/EBITDA exit reflects current market multiples, while the perpetuity method with 3.00% growth is more conservative. The base case averages both methods.

✓

Model and market roughly agree

Market-implied terminal growth of 2.33% is close to the model's 3.00% (only 67bps apart). The DCF assumptions are well-aligned with how the market is pricing this stock.

✓

Strong cash flow conversion

Year 10 FCF/EBITDA conversion of 66.77% indicates efficient cash generation. FCF reaches $1.9B by Year 10 (14.51% FCF margin).

Weighted Average Cost of Capital (WACC)

Cost of Equity (CAPM)

Risk-Free Rate (Rf)4.50%

Beta (β)1.00

Market Risk Premium4.50%

*Using current implied premium (4.5% per Damodaran 2026), not historical (6.5%)

Cost of Equity (Re)8.98%

Cost of Debt

Pre-tax Cost of Debt2.84%

Tax Rate20.75%

After-tax Cost of Debt2.25%

Equity Weight (E/V)76.57%

Debt Weight (D/V)23.43%

WACC Calculation

WACC = (E/V × Re) + (D/V × Rd × (1-Tc))

WACC = (76.57% × 8.98%) + (23.43% × 2.25%)

= 7.41%

10-Year Free Cash Flow Projections(showing years 1, 3, 5, 7, 10)

Year	Year 1	Year 3	Year 5	Year 7	Year 10
Revenue	$14.7B	$16.2B	$15.2B	$13.0B	$13.0B
EBIT	$1.8B	$2.0B	$1.8B	$1.9B	$2.3B
Tax	$368M	$406M	$382M	$402M	$468M
NOPAT	$1.4B	$1.5B	$1.5B	$1.5B	$1.8B
+ Depreciation	$635M	$700M	$658M	$561M	$560M
- Capex	$488M	$538M	$506M	$432M	$431M
- Δ NWC	$70M	$77M	-$205M	-$82M	$37M
Free Cash Flow	$1.5B	$1.6B	$1.8B	$1.7B	$1.9B
Discount Factor	0.931	0.807	0.700	0.606	0.489
Present Value	$1.4B	$1.3B	$1.3B	$1.1B	$920M

FCF Formula: Free Cash Flow = NOPAT + Depreciation - Capex - Change in Net Working Capital

Terminal Value Calculation

Perpetuity Growth Method

Year 10 FCF$1.9B

Terminal Growth Rate3.00%

WACC7.41%

TV = FCF₁₀ × (1+g) / (WACC-g)

Terminal Value$43.9B

PV of Terminal Value$21.5B

Exit Multiple Method

Year 10 EBITDA$2.8B

Exit Multiple (EV/EBITDA)24.0x

TV = EBITDA₁₀ × Exit Multiple

Terminal Value$67.6B

PV of Terminal Value$33.1B

Valuation Summary

Perpetuity Growth Method

PV of Projected FCFs$11.7B

PV of Terminal Value$21.5B

Enterprise Value$33.2B

(-) Net Debt$6.7B

Equity Value$26.5B

Shares Outstanding83M

Price per Share$318.73

Exit Multiple Method

PV of Projected FCFs$11.7B

PV of Terminal Value$33.1B

Enterprise Value$44.7B

(-) Net Debt$6.7B

Equity Value$38.1B

Shares Outstanding83M

Price per Share$457.64

Pure Model Fair Value

$388.18

Average of perpetuity growth and exit multiple methods (before market calibration)

Sensitivity AnalysisPrice per Share

WACC ↓ / Growth →	2.00%	2.50%	3.00%	3.50%	4.00%
5.41%	$514.19	$549.74	$600.06	$653.67	$624.71
6.41%	$425.87	$444.65	$468.93	$501.58	$547.80
7.41%	$363.24	$374.44	$388.18	$405.44	$427.77
8.41%	$315.14	$322.37	$330.92	$341.23	$353.87
9.41%	$276.33	$281.25	$286.94	$293.58	$301.46

How to read: This table shows how the valuation changes with different WACC (discount rate) and terminal growth rate assumptions. Green = undervalued, Red = overvalued.

Scenario Analysis

Bear Case

$334.63

18.2% vs current

• -25% vs analyst consensus
• Terminal growth: 2.5%
• Beta: 1.25

Base Case

$388.18

37.2% vs current

• Analyst consensus
• Terminal growth: 3.0%
• Beta: 1.00

Bull Case

$439.70

55.4% vs current

• +25% vs analyst consensus
• Terminal growth: 3.5%
• Beta: 0.85

Key Assumptions & Drivers✓ Using Analyst Consensus Estimates• Healthcare Sector

Growth Assumptions (Select Years)

Year 1 Revenue Growth5.19%

Year 3 Revenue Growth5.15%

Year 5 Revenue Growth-12.20%

Year 7 Revenue Growth-6.12%

Year 10 Revenue Growth3.00%

Terminal Growth Rate3.00%

Margin & Efficiency

Current EBIT Margin12.08%

Terminal EBIT Margin20.00%

Tax Rate20.75%

Historical Capex / Rev3.33%

NWC / Revenue9.70%

Key Drivers: Revenue growth, operating margin expansion, capex efficiency, and working capital management are the primary drivers of cash flow generation. Terminal value assumptions significantly impact final valuation.

Institutional-Grade Methodology

Actual Company Data: Revenue, EBIT, Capex, NWC, Tax Rate, Interest Expense, Beta

Market Assumptions: Risk-free: 4.5% (10Y), MRP: 4.5% (Damodaran 2026), Exit: 24x EV/EBITDA (Healthcare sector)

This DCF model is for informational purposes only. Projections are based on assumptions that may not materialize. Past performance does not guarantee future results. Consult a financial advisor before making investment decisions.

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance